Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 55
- Registration Number
- NCT02431429
- Locations
- 🇧🇴
Funderama, Santa Cruz, Bolivia
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Registration Number
- NCT02429505
- Locations
- 🇺🇸
Fast-Track Drugs and Biologics, LLC, Poolesville, Maryland, United States
Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 42
- Registration Number
- NCT02429518
- Locations
- 🇧🇴
Funderma, Santa Cruz, Bolivia
Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 2
- Registration Number
- NCT02427308
- Locations
- 🇺🇸
Fast Track, North Potomac, Maryland, United States
Miltefosine to Treat Mucocutaneous Leishmaniasis
Phase 2
Completed
- Conditions
- Cutaneous LeishmaniasisMucosal Leishmaniasis
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 4
- Registration Number
- NCT01050907
- Locations
- 🇺🇸
For this treatment IND, each Physician entered patients at his/her own facility. Below data is for protocol central contact:, Bethesda, Maryland, United States
🇺🇸NIH, Bethesda, Maryland, United States
News
No news found